Anindita Roy

Clinician Scientist in Paediatric Haematology, Department of Paediatrics, University of Oxford. Honorary Clinical Lecturer in Paediatric Haematology, Great Ormond Street Hospital, London

Qualifications
MBBS, DCH, DNB(Paeds), MRCPCH, PhD

Present Appointment
Bloodwise Clinician Scientist in Paediatric Haematology,
University of Oxford, Oxford and Great Ormond Street Hospital London, UK

Previous Experience
- NIHR Academic Clinical Lecturer in Paediatric Haematology, Imperial College London
- Leukaemia Research Fund Clinical Research Training Fellowship, Imperial College London, UK
- London Deanery Specialist Registrar Training Program in Paediatrics
- Cancer Research UK Clinical Fellowship in Paediatric Oncology
- Senior House Officer in Paediatrics, London, UK
- Postgraduate Paediatric Training in CMCH, Vellore, India
- Undergraduate training MBBS in CMCH, Vellore, India

Grants and fellowships
- Cancer Research UK Clinical Fellowship (2003-2004)
- Leukaemia Research Fund Clinical Research Training Fellowship (2007-2011)
- National Institute for Health Research Academic Clinical Lectureship (2011-2015)
- EHA-ASH Translational Research Training in Haematology fellowship (2015)
- Bloodwise Clinician Scientist award (2015- 2019)
- Lady Tata Memorial Trust International Fellowship (2016-2017)
- University of Oxford John Fell Fund grant (2016-2017)
- MRC Discovery award (2016-2017)
- University of Oxford John Fell Fund grant (2017-2018)

Major academic interests
Paediatric Haematology

In our lab, we are investigating the link between human fetal haematopoiesis and the origin and biology of childhood leukaemia. In particular, we are interested in the pathogenesis of infant leukaemia, which is a refractory disease that invariably originates *in utero*.
I joined the Department of Paediatrics at Oxford as a Clinician Scientist in Paediatric Haematology in June 2015, having initially followed a clinical career pathway in Paediatrics followed by Academic Paediatric Haematology. The focus of my research for the last eight years has been in understanding human fetal haematopoiesis. My original research at Imperial College London (2007-2015) involved the characterisation of trisomy 21 associated perturbation of human fetal haematopoiesis. I subsequently worked further on understanding the ontogeny of human fetal B lymphoid development and the results of this research point to a link between fetal lymphopoiesis and infant ALL that may be key to understanding the origins of this biologically unique leukaemia.

The main focus of my current research is to study human fetal B lymphopoiesis in order to elucidate the origins of childhood leukaemia, in particular infant ALL. More specifically, my research aims to identify and characterise the target fetal cell population for leukaemia initiation in infant ALL. I am also a member of Prof Irene Roberts' team trying to understand how trisomy 21 perturbs fetal haematopoiesis and its implications for Down syndrome associated and other leukaemias in children.